Search icon Open mobile navigation
Dr Saam Sedehizadeh at the University of Nottingham will test chemicals for the potential to treat myotonic dystrophy.
Dr Saam Sedehizadeh at the University of Nottingham will test chemicals for the potential to treat myotonic dystrophy.
Dr Saam Sedehizadeh at the University of Nottingham will test chemicals for the potential to treat myotonic dystrophy.
Investing in gene therapy to advance treatments for muscle-wasting conditions
Investing in gene therapy to advance treatments for muscle-wasting conditions
Investing in gene therapy to advance treatments for muscle-wasting conditions
Professor George Dickson and his team plan to develop a novel gene therapy approach for Duchenne muscular dystrophy that is aimed at delivering a functional, full-size dystrophin gene to muscle cells using a harmless virus.
Professor George Dickson and his team plan to develop a novel gene therapy approach for Duchenne muscular dystrophy that is aimed at delivering a functional, full-size dystrophin gene to muscle cells using a harmless virus.
Professor George Dickson and his team plan to develop a novel gene therapy approach for Duchenne muscular dystrophy that is aimed at delivering a functional, full-size dystrophin gene to muscle cells using a harmless virus.

Campaign April 2017

We hope you enjoy reading your spring edition of Campaign, the newsletter that keeps you connected with the work you help fund.
We hope you enjoy reading your spring edition of Campaign, the newsletter that keeps you connected with the work you help fund.
Professor Dame Kay Davies and her colleagues aim to find drugs with the potential to increase levels of a protein called utrophin which could compensate for the lack of dystrophin seen in boys with Duchenne muscular dystrophy.
Professor Dame Kay Davies and her colleagues aim to find drugs with the potential to increase levels of a protein called utrophin which could compensate for the lack of dystrophin seen in boys with Duchenne muscular dystrophy.
Professor Dame Kay Davies and her colleagues aim to find drugs with the potential to increase levels of a protein called utrophin which could compensate for the lack of dystrophin seen in boys with Duchenne muscular dystrophy.

Target MD - Issue 1 - 2017

Welcome to the first edition of Target MD for 2017. We hope you’ll enjoy reading about the work we are – and have been – doing to beat muscle-wasting conditions.
Welcome to the first edition of Target MD for 2017. We hope you’ll enjoy reading about the work we are – and have been – doing to beat muscle-wasting conditions.
In this PhD studentship, Prof Michael Duchen aims to study how the genetic fault that causes the core myopathies can affect specialised structures in the cell called mitochondria.
In this PhD studentship, Prof Michael Duchen aims to study how the genetic fault that causes the core myopathies can affect specialised structures in the cell called mitochondria.
In this PhD studentship, Prof Michael Duchen aims to study how the genetic fault that causes the core myopathies can affect specialised structures in the cell called mitochondria.
Subscribe to